Please use this identifier to cite or link to this item:
|Title:||Alzheimer's disease: Channeling APP to non-amyloidogenic processing|
Non-steroidal anti-inflammatory drugs
Rho-associated protein kinase
|Citation:||Tang, B.L. (2005). Alzheimer's disease: Channeling APP to non-amyloidogenic processing. Biochemical and Biophysical Research Communications 331 (2) : 375-378. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2005.03.074|
|Abstract:||A good number of pharmacologic agents have over the years been touted as potentially beneficial in either preventing the onset or delay the progression of Alzheimer's disease. These include compounds such as non-steroidal anti-inflammatory drugs (NSAIDs) (HMG-CoA reductase inhibitors (statins)) and flavonoids. The underlying mechanisms for the beneficial effect of these agents are by and large attributed to their ability to reduce β-amyloid (Aβ) production and amyloid load in the brain, via inhibition of amyloidogenic γ-secretase activity. Recent reports have now provided mechanistic insights as to how non-amyloidogenic processing might also be enhanced by these seemingly unrelated treatments. Intriguingly, this appears to involve the inhibition of the activity of small GTPase Rho and its effector, the Rho-associated kinase, ROCK. Dietary caloric restriction (CR) also enhances non-amyloidogenic processing of APP, and this may be part of a more general anti-aging effect of CR mediated by gene expression changes downstream of the activity of the histone deacetylase SIRT1. © 2005 Elsevier Inc. All rights reserved.|
|Source Title:||Biochemical and Biophysical Research Communications|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 20, 2018
WEB OF SCIENCETM
checked on Apr 23, 2018
checked on May 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.